The COVID-19 pandemic has disproportionately impacted immunocompromised patients.
This diverse group is at increased risk for impaired vaccine responses, progression to …

Approximately 3% of US adults are immunocompromised and less capable of fighting
infections such as SARS-CoV-2 (the causative agent of COVID-19). Individuals may be …

The clinical implications of COVID-19 have changed since SARS-CoV-2 first emerged in
humans. The current high levels of population immunity, due to prior infection and/or …

Background Available data show that COVID-19 vaccines may be less effective in
immunocompromised populations, who are at increased risk of severe COVID-19 …

Purpose While COVID-19 vaccine emergency use authorization (EUA) deemed the vaccines
to be effective and safe for public use, the phase 3 trials leading to EUA predominantly …

Individuals with compromised immune systems, whether because of immunodeficiency or
immuno suppressive therapy, are among those most susceptible to COVID19. In fact, people …

The COVID-19 pandemic caused by SARS-CoV-2 has resulted in millions of cases and
hundreds of thousands of deaths. Beyond there being no available antiviral therapy …

Since the beginning of vaccination programs against COVID-19 in different countries,
several populations such as patients with specific immunological conditions have been …

Background We studied humoral responses after coronavirus disease 2019 (COVID-19)
vaccination across varying causes of immunodeficiency. Methods Prospective study of fully …

SARS-COV-2 vaccines have been shown to be efficacious primarily in healthy volunteer
populations and population level studies. Immune responses following SARS-CoV-2 …